AC Immune SA (NASDAQ: ACIU) is 23.98% higher on its value in year-to-date trading and has touched a low of $4.07 and a high of $13.00 in the current 52-week trading range. The ACIU stock was last observed hovering at around $5.78 in the last trading session, with the day’s gains setting it 0.63% off its average median price target of $10.96 for the next 12 months. It is also 54.64% off the consensus price target high of $14.13 offered by 4 analysts, but current levels are -45.02% lower than the price target low of $4.42 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $6.41, the stock is 19.81% and 22.56% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.19 million and changing 10.90% at the moment leaves the stock -1.29% off its SMA200. ACIU registered -31.08% loss for a year compared to 6-month loss of -6.56%. The firm has a 50-day simple moving average (SMA 50) of $1.79% and a 200-day simple moving average (SMA200) of $1.66M.
The stock witnessed a 30.55% gain in the last 1 month and extending the period to 3 months gives it a 24.95%, and is 20.49% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.60% over the week and 5.48% over the month.
AC Immune SA (ACIU) has around 115 employees, a market worth around $451.90M and $17.90M in sales. Distance from 52-week low is 57.49% and -50.69% from its 52-week high. The company has generated returns on investments over the last 12 months (16.20%).
AC Immune SA (ACIU) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for AC Immune SA (ACIU) is a “Overweight”. 4 analysts offering their recommendations for the stock have an average rating of 1.70, where 1 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
AC Immune SA is expected to release its quarterly report on 05/12/2021 and quarterly earnings per share for the current quarter are estimated at -$0.27 with sales reaching $1.56M over the same period.The EPS is expected to grow by 177.60% this year, but quarterly earnings will post -84.80% year-over-year. Quarterly sales are estimated to grow 41.20% in year-over-year returns.
AC Immune SA (ACIU) Top Institutional Holders
68 institutions hold shares in AC Immune SA (ACIU), with 33.8M shares held by insiders accounting for 46.99% while institutional investors hold 56.25% of the company’s shares. The shares outstanding are 71.93M, and float is at 37.91M with Short Float at 3.38%. Institutions hold 29.82% of the Float.
The top institutional shareholder in the company is BVF Inc. with over 9.82 million shares valued at $47.92 million. The investor’s holdings represent 13.69% of the ACIU Shares outstanding. As of Sep 29, 2020, the second largest holder is Temasek Holdings (Private) Limited with 2.61 million shares valued at $12.76 million to account for 3.64% of the shares outstanding. The other top investors are Avidity Partners Management, LP which holds 1.55 million shares representing 2.16% and valued at over $7.56 million, while Artal Group S.A. holds 1.39% of the shares totaling 1.0 million with a market value of $4.88 million.
AC Immune SA (ACIU): Who are the competitors?
Omeros Corporation (OMER) is 18.78% up on the 1-year trading charts.